BlossomHill Therapeutics Secures $84M Series B Extension to Advance Precision Oncology Pipeline
BlossomHill Therapeutics, a clinical‑stage biotechnology company focused on creating precision‑designed small molecule medicines for cancer and autoimmune diseases, has significantly expanded its fundraising with an $84 million Series B extension, reinforcing investor confidence as it advances multiple clinical programs. This new financing builds on a previously completed $100 million Series B round, bringing the company’s total capital raised to approximately $257 million, positioning it to accelerate its lead programs and extend its innovative pipeline.
The most recent Series B extension was led by Janus Henderson Investors, Brahma Capital, and BioTrack Capital, with strong participation from existing backers including Cormorant Asset Management, OrbiMed Advisors, Plaisance Capital Management LLC, and Vivo Capital. Together, this mix of new and continuing investors reflects widespread confidence in BlossomHill’s strategy and its potential to address high unmet needs in oncology.
Earlier fundraising for BlossomHill included a $100 million Series B round led by Colt Ventures, with participation from Cormorant Asset Management, OrbiMed Advisors, Vivo Capital, Hercules BioVentures Partners LLC, Plaisance Capital Management LLC, and H&D Asset Management. That round brought the company’s total funding at the time to $173 million and provided the foundation for advancing discovery efforts into clinical development.
BlossomHill was co‑founded by renowned drug designer J. Jean Cui, Ph.D., and biotech business veteran Y. Peter Li, Ph.D., M.B.A., bringing together deep expertise in oncology and precision medicine. Dr. Cui is credited with designing multiple FDA‑approved cancer drugs, including XALKORI®, LOBRENA®, and AUGTYRO®, and that track record forms the scientific backbone of BlossomHill’s discovery engine, focused on creating novel chemical entities that can overcome treatment resistance and improve patient outcomes.
The capital raised through both the original Series B and the extension will directly support the advancement of BlossomHill’s lead clinical programs. One such candidate is BH‑30643, a first‑in‑class macrocyclic, CNS‑active, mutant‑selective OMNI‑EGFR™ inhibitor being evaluated in the Phase 1/2 SOLARA study for patients with locally advanced or metastatic EGFR‑ or HER2‑mutated non‑small cell lung cancer (NSCLC). Early data from the trial have shown promising systemic and central nervous system anti‑tumor activity across challenging EGFR mutation profiles. Another program, BH‑30236, is a novel macrocyclic CDC‑like kinase (CLK) inhibitor targeting dysregulated RNA splicing, currently being evaluated in a first‑in‑human Phase 1/1b trial in relapsed or refractory acute myeloid leukemia (AML) and higher‑risk myelodysplastic syndrome (HR‑MDS). This agent is being studied both as a standalone therapy and in combination with venetoclax, reflecting a strategic approach to address difficult‑to‑treat blood cancers.
BlossomHill’s research strategy emphasizes precision molecular design, leveraging insights into disease biology to craft molecules capable of targeting specific oncogenic drivers and resistance mechanisms. This approach aims to produce differentiated medicines with the potential to deliver meaningful clinical benefits for patients with limited treatment options.
The participation of both new institutional investors and existing backers underscores sustained enthusiasm for BlossomHill’s scientific vision and development progress. Janus Henderson Investors, Brahma Capital, and BioTrack Capital’s leadership in the extension round brings fresh strategic support, while continued backing from firms like Cormorant Asset Management and OrbiMed Advisors highlights confidence in the company’s ability to execute on its pipeline strategy.
With approximately $257 million in funding secured to date, BlossomHill is well‑capitalized to advance its clinical programs, explore potential new indications, and build upon its discovery platforms. This financial foundation positions the company to continue generating important clinical data, expand its therapeutic reach, and work toward delivering new treatment options for patients with cancer and immune‑related diseases.
BlossomHill’s funding achievements not only reflect its scientific promise but also highlight broader investor interest in precision oncology and next‑generation small molecule drug design as essential components of therapeutic innovation.
